InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,660.00
(
0.33%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.20
(
0.29%
)
Bitcoin
62,878.40
(
-0.27%
)
Post# of 15799
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Matrix999

Send PM Follow Ignore
Followers 30
Posts 2380
Boards Moderated 0
Alias Born 06/13/2011

Matrix999

Re: None

Tuesday, 06/21/2016 8:23:53 AM

Tuesday, June 21, 2016 8:23:53 AM

Post# of 15799
The FDA approves Opko Health's (NYSE:OPK) RAYALDEE (calcifediol) extended release capsules for the treatment of patients with secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Market launch will commence later this year.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent OPK News
More OPK News
InvestorsHub NewsWire

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

Start posting your company's news
Only $200 per official company press release!